Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | DexCom Inc. gross profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | DexCom Inc. operating profit margin ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | DexCom Inc. net profit margin ratio improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | DexCom Inc. ROE improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |
ROA | A profitability ratio calculated as net income divided by total assets. | DexCom Inc. ROA deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 exceeding Q1 2023 level. |
Gross Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Gross profit | 623,300) | 546,400) | 462,600) | 541,300) | 494,200) | 449,500) | 398,100) | 472,600) | 446,900) | 417,100) | 343,900) | 399,100) | 340,400) | 284,100) | 256,500) | 309,300) | 246,900) | 206,500) | 168,800) | 222,800) | 168,600) | 153,600) | 118,900) | |||||||
Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Gross profit margin1 | 63.87% | 63.94% | 64.44% | 64.72% | 64.97% | 66.10% | 67.44% | 68.63% | 69.29% | 69.15% | 67.48% | 66.44% | 65.38% | 63.92% | 63.68% | 63.11% | 62.54% | 62.76% | 63.30% | 64.36% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 49.97% | 50.23% | 50.66% | 51.54% | 52.60% | 53.54% | 52.44% | 52.21% | 52.01% | 50.69% | 51.25% | 50.49% | 50.18% | 50.97% | 52.13% | 52.46% | — | — | — | — | — | — | — | |||||||
Cigna Group | 12.28% | 12.19% | 12.39% | 12.44% | 12.39% | 12.40% | 12.30% | 12.41% | 12.77% | 13.13% | 14.04% | 14.43% | 15.05% | 15.49% | 15.30% | 15.57% | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | 15.34% | 15.69% | 16.16% | 16.62% | 16.94% | 17.12% | 17.35% | 17.48% | 17.35% | 17.43% | 17.99% | 18.01% | 18.10% | 18.16% | 17.51% | 17.41% | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 16.86% | 16.89% | 16.90% | 16.79% | 16.85% | 16.79% | 16.89% | 17.09% | 17.30% | 17.57% | 19.38% | 19.71% | 20.18% | 20.43% | 18.70% | 18.77% | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 66.61% | 66.74% | 66.86% | 67.44% | 67.77% | 68.16% | 68.84% | 69.32% | 69.12% | 68.69% | 66.48% | 65.65% | 66.44% | 67.07% | 69.04% | 69.45% | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 66.43% | 67.21% | 67.61% | 67.98% | 67.89% | 67.39% | 66.53% | 65.19% | 63.85% | 64.57% | 65.76% | 67.41% | 68.96% | 69.22% | 69.62% | 70.04% | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 24.16% | 24.08% | 24.20% | 24.09% | 23.74% | 23.51% | 23.31% | 23.60% | 23.75% | 23.80% | 25.79% | 25.62% | 25.83% | 25.95% | 23.52% | 23.19% | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Gross profit margin = 100
× (Gross profitQ3 2023
+ Gross profitQ2 2023
+ Gross profitQ1 2023
+ Gross profitQ4 2022)
÷ (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
= 100 × (623,300 + 546,400 + 462,600 + 541,300)
÷ (975,000 + 871,300 + 741,500 + 815,200)
= 63.87%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | DexCom Inc. gross profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Operating Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Operating income (loss) | 205,500) | 128,100) | 47,200) | 125,400) | 147,500) | 77,000) | 41,300) | 600) | 118,300) | 101,000) | 45,900) | 104,000) | 94,100) | 67,800) | 33,600) | 101,500) | 56,000) | (800) | (14,400) | (164,600) | 13,900) | (4,900) | (30,700) | |||||||
Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | 14.88% | 14.02% | 13.14% | 13.44% | 9.54% | 8.87% | 10.15% | 10.86% | 15.92% | 15.90% | 15.39% | 15.54% | 16.31% | 15.09% | 11.89% | 9.64% | -9.16% | -13.58% | -15.07% | -18.06% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 15.02% | 15.23% | 16.77% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | 13.39% | 12.78% | 14.18% | 14.21% | — | — | — | — | — | — | — | |||||||
Cigna Group | 4.34% | 4.38% | 4.54% | 4.69% | 4.59% | 4.71% | 4.64% | 4.60% | 4.59% | 4.57% | 4.98% | 5.12% | 5.37% | 5.47% | 5.18% | 5.31% | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | 4.04% | 1.88% | 2.33% | 2.41% | 2.02% | 4.35% | 4.39% | 4.54% | 4.75% | 4.93% | 5.19% | 5.19% | 5.44% | 5.36% | 4.89% | 4.69% | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 4.58% | 4.96% | 4.99% | 4.94% | 5.01% | 5.07% | 5.10% | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | 5.59% | 6.99% | 5.47% | 5.49% | — | — | — | — | — | — | — | |||||||
Humana Inc. | 4.42% | 4.55% | 4.45% | 4.11% | 4.09% | 3.57% | 3.73% | 3.80% | 3.40% | 4.97% | 6.60% | 6.56% | 7.77% | 6.77% | 5.09% | 4.96% | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 24.66% | 24.34% | 24.21% | 25.35% | 27.05% | 28.48% | 30.69% | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | 23.95% | 25.86% | 30.52% | 30.69% | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 18.17% | 19.02% | 19.37% | 18.15% | 17.89% | 16.68% | 14.78% | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | 20.67% | 20.47% | 21.25% | 20.51% | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 8.86% | 8.83% | 8.87% | 8.83% | 8.65% | 8.32% | 8.19% | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | 9.55% | 9.89% | 8.12% | 8.19% | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
= 100 × (205,500 + 128,100 + 47,200 + 125,400)
÷ (975,000 + 871,300 + 741,500 + 815,200)
= 14.88%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | DexCom Inc. operating profit margin ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | 120,700) | 115,900) | 48,600) | 91,800) | 101,200) | 50,900) | 97,300) | (19,400) | 70,900) | 62,900) | 40,300) | 355,200) | 72,200) | 46,300) | 19,900) | 92,700) | 45,800) | (10,500) | (26,900) | (179,700) | 46,600) | 30,200) | (24,200) | |||||||
Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | 11.08% | 11.18% | 9.68% | 11.73% | 8.24% | 7.47% | 8.23% | 6.32% | 22.82% | 24.45% | 25.36% | 25.62% | 12.69% | 11.93% | 9.24% | 6.85% | -12.68% | -13.96% | -11.51% | -12.32% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | 10.50% | 9.89% | 11.15% | 11.56% | — | — | — | — | — | — | — | |||||||
Cigna Group | 2.81% | 3.59% | 3.71% | 3.72% | 3.69% | 3.08% | 3.07% | 3.11% | 4.97% | 4.93% | 5.22% | 5.31% | 3.40% | 3.43% | 3.22% | 3.35% | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | 2.48% | 0.86% | 1.20% | 1.29% | 1.00% | 2.66% | 2.68% | 2.72% | 2.67% | 2.60% | 2.74% | 2.68% | 3.00% | 3.14% | 2.77% | 2.59% | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 3.63% | 3.89% | 3.89% | 3.87% | 4.09% | 4.13% | 4.37% | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | 4.26% | 5.27% | 4.42% | 4.66% | — | — | — | — | — | — | — | |||||||
Humana Inc. | 2.97% | 3.45% | 3.28% | 3.03% | 3.07% | 3.52% | 3.52% | 3.54% | 3.31% | 3.13% | 4.78% | 4.43% | 5.67% | 5.00% | 3.89% | 4.20% | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 22.14% | 21.38% | 20.40% | 21.25% | 22.52% | 24.05% | 27.84% | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | 24.45% | 26.07% | 30.11% | 30.80% | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 13.20% | 14.03% | 16.75% | 15.90% | 15.46% | 14.79% | 12.29% | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | 17.11% | 15.11% | 14.41% | 15.16% | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 6.09% | 6.11% | 6.21% | 6.25% | 6.21% | 5.99% | 5.91% | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | 6.66% | 6.94% | 5.63% | 5.76% | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
= 100 × (120,700 + 115,900 + 48,600 + 91,800)
÷ (975,000 + 871,300 + 741,500 + 815,200)
= 11.08%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | DexCom Inc. net profit margin ratio improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |
Return on Equity (ROE)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | 120,700) | 115,900) | 48,600) | 91,800) | 101,200) | 50,900) | 97,300) | (19,400) | 70,900) | 62,900) | 40,300) | 355,200) | 72,200) | 46,300) | 19,900) | 92,700) | 45,800) | (10,500) | (26,900) | (179,700) | 46,600) | 30,200) | (24,200) | |||||||
Stockholders’ equity | 2,267,900) | 2,100,400) | 2,233,000) | 2,131,800) | 1,824,500) | 2,255,900) | 2,189,300) | 2,251,500) | 2,136,100) | 1,997,600) | 1,903,200) | 1,826,500) | 1,499,300) | 1,353,900) | 934,500) | 882,600) | 764,300) | 688,300) | 668,600) | 663,300) | 562,200) | 482,100) | 421,700) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | 16.62% | 17.02% | 13.10% | 16.01% | 12.61% | 8.85% | 9.67% | 6.87% | 24.78% | 26.56% | 27.01% | 27.02% | 15.41% | 15.12% | 15.83% | 11.45% | -22.41% | -24.77% | -19.41% | -19.16% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 13.77% | 13.88% | 15.68% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | 10.78% | 10.17% | 11.84% | 11.86% | — | — | — | — | — | — | — | |||||||
Cigna Group | 11.61% | 14.64% | 15.17% | 14.86% | 14.69% | 11.94% | 11.69% | 11.39% | 17.68% | 16.73% | 17.52% | 16.81% | 11.03% | 11.11% | 10.91% | 11.26% | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | 11.57% | 4.02% | 5.57% | 5.84% | 4.46% | 10.86% | 10.83% | 10.54% | 10.20% | 9.83% | 10.44% | 10.35% | 11.56% | 12.14% | 11.08% | 10.39% | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 15.82% | 16.78% | 16.62% | 16.59% | 17.26% | 17.04% | 17.36% | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | 14.61% | 17.17% | 15.08% | 15.15% | — | — | — | — | — | — | — | |||||||
Humana Inc. | 17.79% | 20.07% | 18.79% | 18.33% | 17.27% | 20.29% | 19.81% | 18.24% | 16.44% | 16.72% | 26.23% | 24.53% | 26.34% | 24.29% | 21.16% | 22.49% | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 12.10% | 12.00% | 11.70% | 11.98% | 11.97% | 11.93% | 13.58% | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | 11.38% | 13.00% | 16.30% | 16.69% | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 7.90% | 8.33% | 9.88% | 9.59% | 9.35% | 9.05% | 7.54% | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | 10.26% | 9.23% | 8.78% | 9.25% | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 25.67% | 25.63% | 25.46% | 25.87% | 26.03% | 25.07% | 23.98% | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | 25.65% | 26.87% | 24.14% | 24.02% | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ Stockholders’ equity
= 100 × (120,700 + 115,900 + 48,600 + 91,800)
÷ 2,267,900 = 16.62%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | DexCom Inc. ROE improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |
Return on Assets (ROA)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net income (loss) | 120,700) | 115,900) | 48,600) | 91,800) | 101,200) | 50,900) | 97,300) | (19,400) | 70,900) | 62,900) | 40,300) | 355,200) | 72,200) | 46,300) | 19,900) | 92,700) | 45,800) | (10,500) | (26,900) | (179,700) | 46,600) | 30,200) | (24,200) | |||||||
Total assets | 6,596,200) | 6,820,700) | 5,515,900) | 5,391,700) | 4,899,200) | 5,217,400) | 5,057,000) | 4,863,600) | 4,775,900) | 4,503,800) | 4,389,800) | 4,290,500) | 3,833,200) | 3,521,800) | 2,447,900) | 2,395,000) | 2,185,700) | 2,065,900) | 1,974,000) | 1,916,000) | 1,114,300) | 1,007,500) | 896,800) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | 5.72% | 5.24% | 5.30% | 6.33% | 4.69% | 3.83% | 4.19% | 3.18% | 11.08% | 11.78% | 11.71% | 11.50% | 6.03% | 5.81% | 6.04% | 4.22% | -7.84% | -8.25% | -6.58% | -6.63% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | 4.90% | 4.52% | 5.36% | 5.43% | — | — | — | — | — | — | — | |||||||
Cigna Group | 3.54% | 4.43% | 4.56% | 4.63% | 4.59% | 3.59% | 3.53% | 3.46% | 5.44% | 5.29% | 5.55% | 5.44% | 3.31% | 3.30% | 3.18% | 3.28% | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | 3.42% | 1.17% | 1.66% | 1.82% | 1.36% | 3.55% | 3.43% | 3.39% | 3.23% | 3.12% | 3.22% | 3.11% | 3.41% | 3.51% | 3.13% | 2.98% | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 5.50% | 5.87% | 5.69% | 5.86% | 6.03% | 6.05% | 6.21% | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | 5.72% | 6.72% | 5.80% | 6.21% | — | — | — | — | — | — | — | |||||||
Humana Inc. | 5.39% | 5.98% | 5.69% | 6.52% | 5.53% | 6.71% | 6.55% | 6.61% | 5.90% | 6.52% | 9.95% | 9.63% | 10.79% | 9.11% | 7.55% | 9.31% | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 10.31% | 10.25% | 10.05% | 10.19% | 10.39% | 10.47% | 12.02% | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | 9.92% | 11.24% | 14.02% | 14.17% | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 4.32% | 4.63% | 5.79% | 5.54% | 5.35% | 5.13% | 4.23% | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | 5.73% | 5.13% | 4.84% | 5.16% | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 7.69% | 7.53% | 7.30% | 8.19% | 7.99% | 7.93% | 7.89% | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | 8.76% | 8.88% | 7.27% | 7.96% | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ Total assets
= 100 × (120,700 + 115,900 + 48,600 + 91,800)
÷ 6,596,200 = 5.72%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | DexCom Inc. ROA deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 exceeding Q1 2023 level. |